Medical Professionals Reference (MPR)Novel D1/D5 Agonist Juvmo Approved for Parkinson Disease

📋 Regulatory Action / Label Change

The FDA approved Juvmo (tavapadon) for the treatment of adults with Parkinson disease (PD), introducing the first selective D1/D5 dopamine receptor partial agonist for this indication. Approval was supported by the phase 3 TEMPO clinical program, including two studies in early PD patients not receiving levodopa (TEMPO-1 and TEMPO-2) and one study evaluating adjunctive use with levodopa in patients experiencing motor fluctuations (TEMPO-3). Across studies, tavapadon improved patient-reported activities of daily living and increased ON time without troublesome dyskinesia. Regulatory approval provides a new dopaminergic treatment option with both monotherapy and adjunctive indications supported by randomized clinical trial data.

Clinical Considerations

• In TEMPO-1 (n=529), tavapadon produced statistically significant improvement in MDS-UPDRS Part II activities-of-daily-living scores versus placebo at 26 weeks (-1.6 and -1.7 vs +0.9; P<.0001).
• In TEMPO-2 (n=304), flexible-dose tavapadon demonstrated a significant improvement in MDS-UPDRS Part II score compared with placebo (-1.5 vs 0.0; P=.0007).
• In TEMPO-3 (n=507), adjunctive tavapadon increased daily ON time without troublesome dyskinesia by 1.7 hours versus 0.6 hours with placebo plus levodopa (P<.0001).
• Tavapadon also reduced OFF time in levodopa-treated patients (-1.9 hours vs -0.9 hours; P=.0006).
• Common adverse reactions included nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety.
• Prescribing information includes warnings regarding hypotension/orthostatic hypotension, impulse-control behaviors, hallucinations or psychotic-like behavior, and dyskinesia.

Practice Applications

• Review tavapadon as a newly available FDA-approved option for adults with Parkinson disease in both early-stage and levodopa-treated settings.
• Evaluate patient-specific goals when considering monotherapy versus adjunctive treatment approaches.
• Monitor for dopaminergic adverse effects, including neuropsychiatric symptoms, dyskinesia, and orthostatic hypotension.
• Discuss dose titration requirements and potential drug-interaction considerations when initiating therapy.
• Interpret the approval in the context of phase 3 evidence demonstrating symptomatic benefit rather than disease-modifying effects.